Tags

Type your tag names separated by a space and hit enter

Bacterial vaginosis: review of treatment options and potential clinical indications for therapy.
Clin Infect Dis. 1999 Jan; 28 Suppl 1:S57-65.CI

Abstract

We reviewed data on the treatment of bacterial vaginosis published from 1993 through 1996. For nonpregnant women, we recommend use of metronidazole (500 mg orally twice daily for 7 days), clindamycin vaginal cream (2%, once daily for 7 days), or metronidazole vaginal gel (0.75%, twice daily for 5 days) as the preferred treatment for bacterial vaginosis. For pregnant high-risk women (women with a prior preterm birth), the objective of the treatment is to prevent adverse outcomes of pregnancy, in addition to relief of symptoms. Thus, systemic therapy for possible subclinical upper tract infection as well as medication that has been studied in pregnant women are preferable. Therefore, we recommend metronidazole (250 mg orally three times a day for 7 days). For pregnant low-risk women (women without a prior preterm birth) with symptomatic disease, the main objective of the treatment is to relieve symptoms. We recommend metronidazole (250 mg orally three times a day for 7 days). Data do not support routine treatment of male sex partners.

Authors+Show Affiliations

Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

10028110

Citation

Joesoef, M R., et al. "Bacterial Vaginosis: Review of Treatment Options and Potential Clinical Indications for Therapy." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 28 Suppl 1, 1999, pp. S57-65.
Joesoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis. 1999;28 Suppl 1:S57-65.
Joesoef, M. R., Schmid, G. P., & Hillier, S. L. (1999). Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 28 Suppl 1, S57-65.
Joesoef MR, Schmid GP, Hillier SL. Bacterial Vaginosis: Review of Treatment Options and Potential Clinical Indications for Therapy. Clin Infect Dis. 1999;28 Suppl 1:S57-65. PubMed PMID: 10028110.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. AU - Joesoef,M R, AU - Schmid,G P, AU - Hillier,S L, PY - 1999/2/24/pubmed PY - 1999/2/24/medline PY - 1999/2/24/entrez SP - S57 EP - 65 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 28 Suppl 1 N2 - We reviewed data on the treatment of bacterial vaginosis published from 1993 through 1996. For nonpregnant women, we recommend use of metronidazole (500 mg orally twice daily for 7 days), clindamycin vaginal cream (2%, once daily for 7 days), or metronidazole vaginal gel (0.75%, twice daily for 5 days) as the preferred treatment for bacterial vaginosis. For pregnant high-risk women (women with a prior preterm birth), the objective of the treatment is to prevent adverse outcomes of pregnancy, in addition to relief of symptoms. Thus, systemic therapy for possible subclinical upper tract infection as well as medication that has been studied in pregnant women are preferable. Therefore, we recommend metronidazole (250 mg orally three times a day for 7 days). For pregnant low-risk women (women without a prior preterm birth) with symptomatic disease, the main objective of the treatment is to relieve symptoms. We recommend metronidazole (250 mg orally three times a day for 7 days). Data do not support routine treatment of male sex partners. SN - 1058-4838 UR - https://www.unboundmedicine.com/medline/citation/10028110/Bacterial_vaginosis:_review_of_treatment_options_and_potential_clinical_indications_for_therapy_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/514725 DB - PRIME DP - Unbound Medicine ER -